Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Bullboard Posts
Post by Riverfolkon Mar 04, 2020 11:03am
59 Views
Post# 30765319

News! Expanded phase 1

News! Expanded phase 1

ARCH BIOPARTNERS EXPANDS DOSING IN PHASE I TRIAL FOR METABLOK TO INCREASE DOSE RANGE FOR FUTURE PHASE II STUDIES

Arch Biopartners Inc. is expanding the dose range of Metablok (LSALT peptide) for future phase II trials targeting inflammation in the lung, the kidney and/or the liver by adding a cohort of eight healthy volunteers to receive the highest daily dose tested to date for three consecutive days. Metablok is the Company's lead drug candidate for treating organ damage caused by inflammation.

The three-day dosing of the additional eight volunteers will provide Arch supplemental dosing data, for review by the U.S. FDA, for its future Phase II trials. The expanded trial will allow an option of a higher dose of Metablok to potentially prevent or treat organ inflammation.

Dosing of the eight additional volunteers has begun and dosing is expected to end during March 2020.

The additional cohort of eight people has been added based on the successful dosing and safety of Metablok in the first 44 volunteers. To date, participants have received up to a high single dose of Metablok, or a low or medium daily dose over three days. In all cases, Metablok was well tolerated during the placebo-controlled trial and no drug-related adverse effects were observed.

Metablok Phase I clinical trial

Arch has been conducting the Phase I clinical trial for Metablok with healthy volunteers in Melbourne, Australia. The Phase I trial is a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of Metablok.

Metablok is an inflammation targeting drug and a potential therapeutic agent to prevent organ injury caused by sepsis and ischemia reperfusion injury. Metablok targets a novel neutrophil (white blood cell) adhesion molecule discovered by Arch scientists and reported in the journal Cell in September 2019.

A successful Phase I trial is expected to be followed by a Phase II trial to investigate Metablok's efficacy at preventing inflammation in a vital organ. Arch is considering targeting inflammation related acute kidney injury in patients undergoing cardiac surgery as a first Phase II indication and/or a separate trial to target inflammation in the lungs caused by infection.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch is developing a drug library, led by Metablok, to produce new drug candidates that inhibit organ inflammation caused via the DPEP-1 pathway.

We seek Safe Harbor.


Bullboard Posts